Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62.5M
-
Number of holders
-
349
-
Total 13F shares, excl. options
-
64.3M
-
Shares change
-
-4.22M
-
Total reported value, excl. options
-
$8.24B
-
Value change
-
-$126M
-
Put/Call ratio
-
1.57
-
Number of buys
-
199
-
Number of sells
-
-223
-
Price
-
$128.18
Significant Holders of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) as of Q2 2025
486 filings reported holding BPMC - Blueprint Medicines Corp - Common Stock, par value $0.001 per share as of Q2 2025.
Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC) has 349 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.3M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (6.42M shares), BlackRock, Inc. (6.12M shares), Pentwater Capital Management LP (3.9M shares), STATE STREET CORP (2.23M shares), UBS Group AG (2.17M shares), FIL Ltd (1.76M shares), OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) (1.71M shares), BARCLAYS PLC (1.56M shares), GEODE CAPITAL MANAGEMENT, LLC (1.54M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.46M shares).
This table shows the top 349 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.